国内团队:壳寡糖调节肠道菌群以改善小鼠便秘
创作:yuanzhidoudou 审核:szx 2020年10月25日
  • 洛哌丁胺诱导小鼠便秘,并导致小鼠的肠道菌群紊乱;
  • 壳寡糖显著增加肠动力,抑制洛哌丁胺诱导的肠道屏障损伤及炎症应答,并改善水-电解质平衡,从而增加小鼠的排便次数及粪便的干重与湿重;
  • 壳寡糖在某些门、科及属水平上改善便秘小鼠的肠道菌群失调,以改善胆汁酸及色氨酸的代谢,并增加粪便短链脂肪酸水平;
  • 在抗生素处理后的小鼠中,壳寡糖无法改善小鼠便秘,提示壳寡糖的作用依赖于肠道菌群。
主编推荐语
szx
湖北中医药大学的刘洪涛团队与湖北省中医药研究院的林爱珍团队在Carbohydrate Polymers上发表的一项最新研究,发现在洛哌丁胺诱导的便秘小鼠中,壳寡糖可显著改善小鼠的便秘、增加肠动力、缓解炎症应答、恢复肠道屏障功能,并恢复洛哌丁胺引起的肠道菌群组成及代谢失调,而壳聚糖对便秘的改善作用依赖于肠道菌群。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Chitosan Oligosaccharides attenuate loperamide-induced constipation through regulation of gut microbiota in mice

壳寡糖通过调节小鼠肠道菌群缓解洛哌丁胺诱导的便秘

10.1016/j.carbpol.2020.117218

2020-10-13, Article

Abstract & Authors:展开

Abstract:收起
This study was designed to explore the improvement of chitosan oligosaccharides (COS) on constipation through regulation of gut microbiota. Here, we proved that COS treatment profoundly boosted intestinal motility, restrained inflammatory responses, improved water-electrolyte metabolism and prevented gut barrier damage in constipated mice induced by loperamide. By 16S rDNA gene sequencing, the disbalanced gut microbiota was observed in constipated mice, while COS treatment statistically reversed the abundance changes of several intestinal bacteria at either phylum, family and genus levels, which partly led to the balance in production of intestinal metabolites including bile acids, short-chain fatty acids and tryptophan catabolites. In addition, COS failed to relieve the constipation in mice with intestinal flora depletion, confirming the essentiality of gut microbiota in COS-initiated prevention against constipation. In summary, COS can ameliorate the development of loperamide-induced constipation in mice by remodeling the structure of gut microbial community.

First Authors:
Xiaoyu Zhang

Correspondence Authors:
Aizhen Lin,Hongtao Liu

All Authors:
Xiaoyu Zhang,Huabing Yang,Junping Zheng,Nan Jiang,Guangjun Sun,Xinkun Bao,Aizhen Lin,Hongtao Liu

评论